Clinical Assets
Otlertuzumab is a humanized anti-CD37 fusion protein, based on our ADAPTIR™ (Modular Protein Technology) platform, for potential treatment of chronic lymphocytic leukemia.   LEARN MORE

Preclinical Assets
We have candidates from our ADAPTIR and MVAtor™ (Modified Vaccinia Ankara Vector) platform technologies. All of our candidates have in vitro data, and most have in vivo data and manufacturing proof of concept. 

 

We actively seek to acquire or license marketed products to grow our business and to establish a commercial presence in specialty markets. We seek:
 

• Approved specialty pharma products
• Currently procured biodefense products or product candidates with a high likelihood of procurement

• Biodefense products with government funded development

 

Contact us at BD@ebsi.com.

 

 

Emergent actively partners with experienced R&D companies that align with our strategic objectives and complement our core capabilities.
 
Emergent works with partners to:
 

• Find potential value beyond basic contract arrangements;
• Design relationships that incentivize innovative thinking; and

• Improve the efficiency of the partnership's operations.


 

 

 

 
 

Submit your inquiry! BD@ebsi.com

MEET US

  • Biosciences

    Protein & Antibody Engineering (PEGS)

    May 5 - 9

    Boston, MA

  • Oncology

    American Association for Cancer Research
    April 6 - 9
    San Diego, CA

  • Investor Relations

    UBS Global Healthcare Conference
    May 19-21
    New York, NY

  • Investor Relations

    BofAML Global Healthcare Conference
    May 13-15
    Las Vegas, NV

  • Investor Relations

    Mizuho Healthcare Conference
    May 6
    New York, NY